Latest news with #Alloy
Yahoo
22-05-2025
- Business
- Yahoo
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology. TOKYO & BOSTON, May 22, 2025--(BUSINESS WIRE)--Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base. To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary. Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program, led by Professor Shin Kaneko of Kyoto University's Center for iPS Cell Research and Application (CiRA) in collaboration with Takeda. The iCAR-T platform is noteworthy for (1) being the first iPS CAR-T technology to consistently deliver superior potency over autologous CAR-T in animal studies, and (2) enabling 'off-the-shelf' product profiles that significantly lower costs and increase access. Now, Alloy offers democratized access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform. Alloy's iPS Center of Excellence As of this spring, 10 key members from Takeda's iCAR-T program have formally joined Alloy as founding members of Alloy Cell Therapies, creating the core of a fully integrated drug discovery program leveraging the iCAR-T platform. Alloy further welcomes Dr. Michael Kalos as an Executive Venture Partner of 82VS Venture Studios and a trusted advisor to Alloy Cell Therapies. Michael Kalos – Distinguished BioPharma Executive with key roles that span academia, pharma, and various biotech firms. Contributions include key discoveries that have shaped Immune Oncology and CAR-T development. "Cell Therapy has always been a key modality on our Technology roadmap, and we are thrilled with our partnership with Takeda and Kyoto University," said Errik Anderson, the CEO and founder of Alloy. "We are impressed with how advanced Cell Therapy is in Japan and we are excited to have the iCAR-T members join Alloy as the core members of Alloy's iPS Center of Excellence." "Cell Therapies gave us a compelling reason to establish our site in Japan. Cell Therapy is a stronghold in Japan, and this collaboration will allow Alloy to project the capabilities of Japanese science to the global biopharma markets," added Victor Stone, Chief Executive Officer of Alloy Japan. "Japan has many untapped strengths beyond Cell Therapies. Alloy will continue to expand its activities to leverage that potential, as well as build our franchise in this key market." About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, bispecifics, TCRs, genetic medicines, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy's Innovation Subscriptions offering. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Join the Alloy Therapeutics community by visiting and following Alloy on LinkedIn. View source version on Contacts Victor Stone (Yoshihide Ishii)Chief Executive Officer of Alloy JapanEmail: celltherapies@ Chris BediHead of Strategic Marketing and Product ManagementEmail: communications@ Daniel BoglerEmail: AlloyTherapeutics-TYO@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. ('Alloy'), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base. To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary. Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program, led by Professor Shin Kaneko of Kyoto University's Center for iPS Cell Research and Application (CiRA) in collaboration with Takeda. The iCAR-T platform is noteworthy for (1) being the first iPS CAR-T technology to consistently deliver superior potency over autologous CAR-T in animal studies, and (2) enabling 'off-the-shelf' product profiles that significantly lower costs and increase access. Now, Alloy offers democratized access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform. Alloy's iPS Center of Excellence As of this spring, 10 key members from Takeda's iCAR-T program have formally joined Alloy as founding members of Alloy Cell Therapies, creating the core of a fully integrated drug discovery program leveraging the iCAR-T platform. Alloy further welcomes Dr. Michael Kalos as an Executive Venture Partner of 82VS Venture Studios and a trusted advisor to Alloy Cell Therapies. Michael Kalos – Distinguished BioPharma Executive with key roles that span academia, pharma, and various biotech firms. Contributions include key discoveries that have shaped Immune Oncology and CAR-T development. 'Cell Therapy has always been a key modality on our Technology roadmap, and we are thrilled with our partnership with Takeda and Kyoto University,' said Errik Anderson, the CEO and founder of Alloy. 'We are impressed with how advanced Cell Therapy is in Japan and we are excited to have the iCAR-T members join Alloy as the core members of Alloy's iPS Center of Excellence.' 'Cell Therapies gave us a compelling reason to establish our site in Japan. Cell Therapy is a stronghold in Japan, and this collaboration will allow Alloy to project the capabilities of Japanese science to the global biopharma markets,' added Victor Stone, Chief Executive Officer of Alloy Japan. 'Japan has many untapped strengths beyond Cell Therapies. Alloy will continue to expand its activities to leverage that potential, as well as build our franchise in this key market.' About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, bispecifics, TCRs, genetic medicines, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy's Innovation Subscriptions offering. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Join the Alloy Therapeutics community by visiting and following Alloy on LinkedIn.
Yahoo
23-04-2025
- Business
- Yahoo
10x Banking adds new AI capabilities to core platform
10x Banking has rolled out new AI capabilities designed to enhance its cloud-native core banking platform. These features aim to expedite banking transformation, improve operational efficiency, and support decision-making processes within financial institutions. The AI functionalities will be integrated into 10x Banking's meta core, launched in July of the previous year, which addresses the limitations of traditional core systems while simplifying the transition to a fully cloud-native environment. The 10x Banking platform allows banks to automate the mapping of legacy banking data, thereby expediting core migration processes. The AI product suite from 10x Banking includes three solutions aimed at addressing industry challenges and harnessing the potential of AI in banking. These include AI Migrate, which automates the legacy data mapping process to minimise risk and costs during migration. 10x Banking also launched AI Build, which utilises generative AI for product customisation, allowing banks to create and test innovative products rapidly without engineering hassles. Lastly, AI View offers instant access to critical banking metrics, eliminating the need for manual reporting and reducing dependency on IT resources. Financial institutions will be able to develop and launch new products in days instead of months and gain access to real-time insights without relying on outdated batch reporting from IT teams. The platform is designed to support corporate banks with a core solution that can handle over 100,000 transactions per second and up to 2,000 transactions per individual customer account, outpacing traditional batch transaction speeds. In November 2024, 10x Banking teamed up with Alloy to provide a comprehensive solution for customer onboarding, perpetual KYC and KYB monitoring, and credit decisioning for financial institutions. "10x Banking adds new AI capabilities to core platform" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
10x Banking adds new AI capabilities to core platform
10x Banking has rolled out new AI capabilities designed to enhance its cloud-native core banking platform. These features aim to expedite banking transformation, improve operational efficiency, and support decision-making processes within financial institutions. The AI functionalities will be integrated into 10x Banking's meta core, launched in July of the previous year, which addresses the limitations of traditional core systems while simplifying the transition to a fully cloud-native environment. The 10x Banking platform allows banks to automate the mapping of legacy banking data, thereby expediting core migration processes. The AI product suite from 10x Banking includes three solutions aimed at addressing industry challenges and harnessing the potential of AI in banking. These include AI Migrate, which automates the legacy data mapping process to minimise risk and costs during migration. 10x Banking also launched AI Build, which utilises generative AI for product customisation, allowing banks to create and test innovative products rapidly without engineering hassles. Lastly, AI View offers instant access to critical banking metrics, eliminating the need for manual reporting and reducing dependency on IT resources. Financial institutions will be able to develop and launch new products in days instead of months and gain access to real-time insights without relying on outdated batch reporting from IT teams. The platform is designed to support corporate banks with a core solution that can handle over 100,000 transactions per second and up to 2,000 transactions per individual customer account, outpacing traditional batch transaction speeds. In November 2024, 10x Banking teamed up with Alloy to provide a comprehensive solution for customer onboarding, perpetual KYC and KYB monitoring, and credit decisioning for financial institutions. "10x Banking adds new AI capabilities to core platform" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
16-04-2025
- Business
- Yahoo
Blend Labs, Alloy expand partnership to enhance digital banking security
Blend Labs, an origination platform for digital banking solution, has announced an expansion of its partnership with Alloy, a provider of identity and fraud prevention solutions. This new agreement allows Blend's clients to integrate Alloy's advanced fraud prevention capabilities into their digital banking services more efficiently, aiming to enhance the security of consumer banking experiences. The collaboration builds on an existing relationship between Blend and Alloy, which has already been providing integrated solutions for fraud prevention and compliance within Blend's deposit account and consumer lending offerings. Financial institutions, such as Langley Federal Credit Union, have reported positive outcomes from this joint initiative, stated the two companies. Blend Labs co-founder and CEO Nima Ghamsari said: 'Our partnership with Alloy helps us go beyond expectations, giving financial institutions the security and scalability they need to lend with confidence. 'With this expanded relationship, we're making it even easier and more cost-effective for lenders to access top-tier risk and fraud prevention tools—seamlessly built into their workflows.' The partnership facilitates identity orchestration, enabling lenders to fulfil know your customer (KYC) obligations and conduct fraud screenings by utilising various third-party data sources. Additionally, the implementation of configurable workflows optimises the process by intelligently sequencing data providers, allowing institutions to maintain a balance between security, compliance, and operational efficiency. Alloy chief revenue officer Keith Kettell said: 'By combining our expertise in fraud prevention with Blend's industry-leading consumer banking platform, we're equipping lenders with the tools they need to stay ahead of threats while also automating and simplifying their operations.' Earlier this month, Blend Labs partnered with Prove Identity to improve digital onboarding for lenders on its Consumer Banking platform. This collaboration incorporates the Prove Pre-Fill solution, which is intended to speed up the onboarding process for consumers applying for deposit accounts, credit cards, and loans. "Blend Labs, Alloy expand partnership to enhance digital banking security" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
